GlobalData analyst Shehroz Mahmood notes that Novo Nordisk's amycretin could become the "next frontier" in obesity and T2D.

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

Contineum Therapeutics’ M1 antagonist, PIPE-307, has failed to meet its primary and secondary efficacy endpoints in a Phase II trial in RRMS. Image credit: Andrzej Rostek via ShutterStock.com.

Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting ...

The potential of digital twin technology is growing within the clinical trials landscape. Image credit: Gorodenkoff via ShutterStock.com. In recent years, automation and artificial intelligence (AI) ...

WCG, a tech-enabled partner with over 55 years’ experience accelerating clinical research while safeguarding participant safety, won the Innovation Award in the Ethics Review category in the 2025 ...

Amid geopolitical instability, professionals in the clinical trials segment must look to mitigate risks early through operational flexibility. Image credit: Athanasios Psimadis / Arena International.

Each insight is focused on improving human-centred outcomes, aiming to cut the burden on both subjects and research sites. Credit: metamorworks / Shutterstock.com. WCG has introduced Data & Insights ...

At the 2025 Outsourcing in Clinical Trials DACH conference, industry members discussed the use cases of AI in clinical trials, as well as the hurdles that need to be overcome for its widespread ...

Roche’s oral BTK inhibitor, fenebrutinib, has demonstrated its efficacy in two different subsets of multiple sclerosis (MS) during two late-stage trials. Image credit: illustrissima via ...

The trial enrolled 73 subjects who had not responded satisfactorily to a minimum of one antidepressant during their current episode. Credit: daniiD / Shutterstock.com. Neurocrine Biosciences has ...